Altered PPARgamma expression and activation after transient focal ischemia in rats
- PMID: 17004929
- DOI: 10.1111/j.1460-9568.2006.05037.x
Altered PPARgamma expression and activation after transient focal ischemia in rats
Abstract
Stroke is a devastating disease with limited treatment options. Recently, we found that the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and pioglitazone reduce injury and inflammation in a rat model of transient cerebral ischemia. The mechanism of this protection is unclear, as these agents can act through PPAR-gamma activation or through PPAR-gamma-independent mechanisms. Therefore, we examined PPAR-gamma expression, DNA binding and transcriptional activity following stroke. In addition, we used a PPAR-gamma antagonist, T0070907, to determine the role of PPAR-gamma during ischemia. Using immunohistochemical techniques and real-time PCR, we found low levels of PPAR-gamma mRNA and PPAR-gamma immunoreactivity in nonischemic brain; however, PPAR-gamma expression dramatically increased in ischemic neurons, peaking 24 h following middle cerebral artery occlusion. Interestingly, we found that in both vehicle- and agonist-treated brains, DNA binding was reduced in the ischemic hemisphere relative to the contralateral hemisphere. Expression of a PPAR-gamma target gene, lipoprotein lipase, was also reduced in ischemic relative to nonischemic brain. Both DNA binding and lipoprotein lipase expression were increased by the addition of the PPAR-gamma agonist rosiglitazone. Finally, we found that rosiglitazone-mediated protection after stroke was reversed by the PPAR-gamma antagonist T0070907. Interestingly, infarction size was also increased by T0070907 in the absence of PPAR-gamma agonist, suggesting that endogenous PPAR-gamma ligands may mitigate the effects of cerebral ischemia.
Similar articles
-
Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.Neuroscience. 2005;130(3):685-96. doi: 10.1016/j.neuroscience.2004.10.021. Neuroscience. 2005. PMID: 15590152
-
Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.J Cereb Blood Flow Metab. 2007 Jul;27(7):1327-38. doi: 10.1038/sj.jcbfm.9600438. Epub 2007 Jan 10. J Cereb Blood Flow Metab. 2007. PMID: 17213861
-
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.J Neurochem. 2006 Apr;97(2):435-48. doi: 10.1111/j.1471-4159.2006.03758.x. Epub 2006 Mar 15. J Neurochem. 2006. PMID: 16539667
-
PPAR-gamma: therapeutic target for ischemic stroke.Trends Pharmacol Sci. 2007 May;28(5):244-9. doi: 10.1016/j.tips.2007.03.004. Epub 2007 Apr 9. Trends Pharmacol Sci. 2007. PMID: 17416424 Review.
-
Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.Cardiovasc Res. 2005 Mar 1;65(4):772-81. doi: 10.1016/j.cardiores.2004.12.008. Cardiovasc Res. 2005. PMID: 15721857 Review.
Cited by
-
PPARγ activation blocks development and reduces established neuropathic pain in rats.Neuropharmacology. 2013 Jul;70:236-46. doi: 10.1016/j.neuropharm.2013.01.020. Epub 2013 Feb 13. Neuropharmacology. 2013. PMID: 23415633 Free PMC article.
-
The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.CNS Drugs. 2008;22(1):1-14. doi: 10.2165/00023210-200822010-00001. CNS Drugs. 2008. PMID: 18072811 Review.
-
IUGR disrupts the PPARγ-Setd8-H4K20me(1) and Wnt signaling pathways in the juvenile rat hippocampus.Int J Dev Neurosci. 2014 Nov;38:59-67. doi: 10.1016/j.ijdevneu.2014.07.008. Epub 2014 Aug 11. Int J Dev Neurosci. 2014. PMID: 25107645 Free PMC article.
-
PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury.Mol Neurobiol. 2017 Oct;54(8):5973-5987. doi: 10.1007/s12035-016-0131-9. Epub 2016 Sep 29. Mol Neurobiol. 2017. Retraction in: Mol Neurobiol. 2024 Jul;61(7):4924. doi: 10.1007/s12035-024-04164-x PMID: 27686077 Retracted.
-
The Unveiling of Therapeutic Targets for Alzheimer's Disease: An Integrative Review.Curr Top Med Chem. 2024;24(10):850-868. doi: 10.2174/0115680266282492240220101049. Curr Top Med Chem. 2024. PMID: 38424435 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical